- Home
- BODI vs IMMX Comparison
BODI vs IMMX Comparison
Compare BODI & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BODI
- IMMX
- Stock Information
- Founded
- BODI 1998
- IMMX 2014
- Country
- BODI United States
- IMMX United States
- Employees
- BODI N/A
- IMMX N/A
- Industry
- BODI Industrial Machinery/Components
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- BODI Industrials
- IMMX Health Care
- Exchange
- BODI Nasdaq
- IMMX Nasdaq
- Market Cap
- BODI 49.0M
- IMMX 50.1M
- IPO Year
- BODI N/A
- IMMX 2021
- Fundamental
- Price
- BODI $6.25
- IMMX $1.65
- Analyst Decision
- BODI Strong Buy
- IMMX Strong Buy
- Analyst Count
- BODI 3
- IMMX 1
- Target Price
- BODI $10.67
- IMMX $7.00
- AVG Volume (30 Days)
- BODI 13.5K
- IMMX 46.9K
- Earning Date
- BODI 05-05-2025
- IMMX 05-08-2025
- Dividend Yield
- BODI N/A
- IMMX N/A
- EPS Growth
- BODI N/A
- IMMX N/A
- EPS
- BODI N/A
- IMMX N/A
- Revenue
- BODI $418,796,000.00
- IMMX N/A
- Revenue This Year
- BODI N/A
- IMMX N/A
- Revenue Next Year
- BODI $1.13
- IMMX N/A
- P/E Ratio
- BODI N/A
- IMMX N/A
- Revenue Growth
- BODI N/A
- IMMX N/A
- 52 Week Low
- BODI $5.14
- IMMX $1.26
- 52 Week High
- BODI $10.80
- IMMX $3.13
- Technical
- Relative Strength Index (RSI)
- BODI 38.68
- IMMX 43.22
- Support Level
- BODI $6.61
- IMMX $1.36
- Resistance Level
- BODI $7.55
- IMMX $1.90
- Average True Range (ATR)
- BODI 0.67
- IMMX 0.17
- MACD
- BODI -0.09
- IMMX -0.01
- Stochastic Oscillator
- BODI 0.00
- IMMX 41.49
About BODI The Beachbody Company Inc. Class A Common Stock
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in two operating segments, Beachbody and Other.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.